BridgeMD
The effect of Janus Kinase inhibitors on the heart in Rheumatoid Arthritis
EU CTIS ID: 2025-520710-58-00
What this study is testing
To investigate the effect of Janus kinase inhibitors in patients with rheumatoid arthritis on cardiac function, myocardial inflammation and coronary plaque morphology.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis of RA according to the ACR/EULAR 2010 criteria
- Moderate to high disease activity defined as a Disease Activity Score 28 (DAS28) ≥3.2
- Clinical indication for treatment with a JAK inhibitor
- No changes to pharmacological therapy in last 4 weeks
- Age 40-70 years
You likely can't join if
- Symptoms of angina or heart failure
- Participation in a trial with an investigational drug or treatment
- History of noncompliance with medical therapy
- Unwilling or unable to provide written informed consent or comply with the study protocol
- Life expectancy less than 1 year
- Left main stenosis >50% on CCTA
See the full eligibility criteria
- Diagnosis of RA according to the ACR/EULAR 2010 criteria
- Moderate to high disease activity defined as a Disease Activity Score 28 (DAS28) ≥3.2
- Clinical indication for treatment with a JAK inhibitor
- No changes to pharmacological therapy in last 4 weeks
- Age 40-70 years
- Symptoms of angina or heart failure
- Participation in a trial with an investigational drug or treatment
- History of noncompliance with medical therapy
- Unwilling or unable to provide written informed consent or comply with the study protocol
- Life expectancy less than 1 year
- Left main stenosis >50% on CCTA
- History of hypertension, dyslipidaemia, diabetes mellitus, myocardial infarction, coronary revascularization, cardiac transplantation, pacemaker or implantable cardioverter defibrillator implantation, valvular disease, heart failure, second or third degree heart block, (supra)ventricular tachycardia or frequent premature atrial or ventricular complexes.
- Contraindications to intravenous adenosine administration (e.g. Chronic Obstructive Pulmonary Disease stage IV or asthma, systemic hypotension with mean arterial blood pressure <70mm Hg, second or third degree AV nodal conduction disturbances)
- Contraindications to CMR or CCTA (e.g. claustrophobia, ferromagnetic implants, known allergy to iodinated or gadolinium based contrast agents, weight or size exceeding the limits of the CMR or CCTA scanner.
- Contraindications to treatment with JAK inhibitors (e.g. history of deep vein thrombosis or pulmonary embolism, known malignancy, planned major surgery, active infection)
- Current smoking
- Estimated Glomerular Filtration Rate <30 mL/min/1.73m2
- Pregnancy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.